ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2021

Solid sales growth during January; Zinzino group revenue increased with a total of 26%, compared with the previous year.

The revenue in January for Zinzino's sales markets increased by 30% to SEK 102.3 (78.7) million due to strong growth in several regions. Faun Pharma's external sales decreased by 23% and amounted to SEK 5.3 (6.9) million. Overall, the Group increased revenues by 26% to SEK 107.6 (85.6) million compared with the previous year.

Revenues distributed as follows:

 
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 11:00 the 3rd of February 2021.

Zinzino AB (publ.) is a global direct sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market.